A Phase I, Randomised, Double-Blind, Placebo-Controlled,AscendingSingle- and Repeat-Dose Study of the Safety,Tolerability andPharmacokinetics of Orally Administered PRN473
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs PRN 473 (Primary)
- Indications Arthritis
- Focus Adverse reactions; First in man
- Sponsors Principia Biopharma
- 13 Mar 2014 Status changed from recruiting to completed, as per Australian New Zealand Clinical Trials Registry.
- 21 Nov 2013 Planned number of patients changed from 106 to 114 as reported by Australian New Zealand Clinical Trials Registry.
- 12 Nov 2013 According to the Australian New Zealand Clinical Trials Registry record, the anticipated date of last participant recruited/enrolled is 7/04/2014.